| Literature DB >> 25002810 |
Shadi S Yarandi1, Thomas Runge1, Lei Wang1, Zhijian Liu1, Yueping Jiang1, Saurabh Chawla1, Kevin E Woods1, Steven Keilin1, Field F Willingham1, Hong Xu1, Qiang Cai1.
Abstract
Despite using imaging studies, tissue sampling, and serologic tests about 5-10% of surgeries done for presumed pancreatic malignancies will have benign findings on final pathology. Endoscopic ultrasound (EUS) is used with increasing frequency to study pancreatic masses. The aim of this study is to examine the effect of EUS on prevalence of benign diseases undergoing Whipple over the last decade. Patients who underwent Whipple procedure for presumed malignancy at Emory University Hospital from 1998 to 2011 were selected. Demographic data, history of smoking and drinking, history of diabetes and pancreatitis, imaging data, pathology reports, and tumor markers were extracted. 878 patients were found. 95 (10.82%) patients had benign disease. Prevalence of benign finding had increased over the recent years despite using more EUS. Logistic regression models showed that abdominal pain (OR: 5.829, 95% CI 2.681-12.674, P ≤ 0.001) and alcohol abuse (OR: 3.221, CI 95%: 1.362-7.261, P: 0.002) were predictors of benign diseases. Jaundice (OR: 0.221, 95% CI: 0.084-0.58, P: 0.002), mass (OR: 0.145, 95% CI: 0.043-0.485, P: 0.008), and ductal dilation (OR: 0.297, 95% CI 0.134-0.657, P: 0.003) were associated with malignancy. Use of imaging studies, ERCP, and EUS has not decreased the percentage of benign findings after surgery for presumed pancreatic malignancy.Entities:
Year: 2014 PMID: 25002810 PMCID: PMC4068051 DOI: 10.1155/2014/701535
Source DB: PubMed Journal: Diagn Ther Endosc ISSN: 1026-714X
Figure 1Distribution of number of surgeries and percentage of benign pathologic findings per year. Number of Whipple surgeries performed each year for presumed malignant disease at EUH from 1998 to 2011. Number and percentage of benign findings are listed above each bar. As illustrated in the figure, total number of surgeries and percentage of benign findings have been increased over the years.
Demographic data of patients with benign disease.
| Category | Number (percent) |
|---|---|
| Gender | |
| Male | 52 (54.7) |
| Female | 43 (45.3) |
| Race | |
| White | 65 (68.4) |
| African American | 28 (29.5) |
| Asian | 1 (1.1) |
| Hispanic | 1 (1.1) |
| Past medical history | |
| Diabetes | 10 (10.5) |
| Pancreatitis | 40 (42.1) |
| Social history | |
| Smoking | 57 (60) |
| Alcohol | 42 (44.2) |
| Presenting symptom | |
| Abdominal pain | 91 (95.8) |
| Jaundice | 25 (26.3) |
| Weight loss | 69 (72.6) |
Figure 2Number of EUS/FNA performed between 1998 and 2011 in patients with benign disease who underwent Whipple procedure for presumed malignancy. Number of EUS/FNA in patients with benign findings after Whipple procedure performed each year for presumed malignant disease at EUH from 1998 to 2011. As illustrated, number of EUS/FNA performed has increased over the years, but has not led to decreased number of Whipple procedures performed for benign diseases.
Imaging modalities and findings of patients with benign disease.
| Category | Number (percent) |
|---|---|
| Imaging type | |
| MRI | 85 (89.5) |
| EUS | 25 (26.3) |
| ERCP | 32 (33.7) |
| Space occupying lesion | |
| Mass | 56 (58.9) |
| Size | 13.71 (15.43 SD) |
| Cyst | 23 (24.2) |
| Size | 7.6 (16.48) |
| Abnormal enhancement | |
| Periductal | 7 (7.36) |
| Decreased enhancement | 13 (13.68) |
| Increased early enhancement | 24 (25.6) |
| Increased delayed enhancement | 18 (18.94) |
| Other | |
| Inflammation | 32 (33.7) |
| Duct dilation | 62 (65.3) |
| Lymph node | 6 (6.3) |
| Vascular involvement | 10 (10.5) |
Frequency of Benign Findings.
| Type | Number (percent) |
|---|---|
| PLSP autoimmune pancreatitis | 6 (6.3) |
| Chronic fibrosing pancreatitis | 20 (21) |
| Chronic pancreatitis | 18 (18.94) |
| Focal active pancreatitis | 11 (11.57) |
| Perideudonal pancreatitis | 14 (14.73) |
| AVM | 1 (1) |
| Chronic pancreatitis with infection | 2 (2.1) |
| Granulomatose pancreatitis | 1 (1) |
| Necrotizing pancreatitis | 5 (5.26) |
| Pseudotumoral pancreatitis | 6 (6.3) |
| Focal fat necrosis | 2 (2.1) |
| Chronic pancreatitis with ductal stone | 2 (2.1) |
| Lipoma | 1 (1) |
| Lipomatose pseudohypertrophy | 1 (1) |
| Intraductal adenoma | 1 (1) |
| Xanthogranulomatous inflammation | 1 (1) |
| Thrombosed pseudoaneurysm | 1 (1) |
| Chronic pancreatitis with thrombosed vessels | 1 (1) |
| Chronic pancreatitis due to deudonal diverticulum | 1 (1) |
Logistic regression models for benign findings in patients undergoing Whipple procedure for presumed malignancy.
| Variable | OR | 95% CI |
|
|---|---|---|---|
| Gender (female) | 1.229 | 0.625–2.49 | 0.55 |
| Race (African American) | 0.804 | 0.390–1.66 | 0.55 |
| Smoking | 0.966 | 0.445–2.09 | 0.93 |
| Chronic pancreatitis | 1.072 | 0.184–1.168 | 0.102 |
| Alcohol abuse | 3.221 | 1.362–7.261 | 0.002 |
| Abdominal pain | 5.829 | 2.681–12.674 | <0.001 |
| Jaundice | 0.221 | 0.084–0.58 | 0.002 |
| Weight loss | 1.566 | 0.94–1.89 | 0.078 |
| Mass | 0.145 | 0.043–0.485 | 0.008 |
| Dilation of ducts | 0.297 | 0.134–0.657 | 0.003 |
| Lymphadenopathy | 0.874 | 0.478–4.736 | 0.485 |
| Vascular invasion | 1.00 | 0.357–2.80 | 0.99 |